Omalizumab pretreatment decreases acute reactions after rush immunotherapy for ragweed-induced seasonal allergic rhinitis
TB Casale, WW Busse, JN Kline, ZK Ballas… - Journal of Allergy and …, 2006 - Elsevier
BACKGROUND: Rush immunotherapy (RIT) presents an attractive alternative to standard
immunotherapy. However, RIT carries a much greater risk of acute allergic reactions,
including anaphylaxis. OBJECTIVES: We hypothesized that omalizumab, a humanized
monoclonal anti-IgE antibody, would be effective in enhancing both safety and efficacy of
RIT. METHODS: Adult patients with ragweed allergic rhinitis were enrolled in a 3-center, 4-
arm, double-blind, parallel-group, placebo-controlled trial. Patients received either 9 weeks …
immunotherapy. However, RIT carries a much greater risk of acute allergic reactions,
including anaphylaxis. OBJECTIVES: We hypothesized that omalizumab, a humanized
monoclonal anti-IgE antibody, would be effective in enhancing both safety and efficacy of
RIT. METHODS: Adult patients with ragweed allergic rhinitis were enrolled in a 3-center, 4-
arm, double-blind, parallel-group, placebo-controlled trial. Patients received either 9 weeks …